Statin therapy and autoimmune disease: from protein prenylation to immunomodulation

Statins have been prescribed extensively for their cholesterol-lowering properties and efficacy in cardiovascular disease. However, compelling evidence now exists that statins also have extensive immunomodulatory properties that operate independently of lipid lowering. Consequently, much attention has been directed towards their potential as therapeutic agents for the treatment of autoimmune disease. Modulation of post-translational protein prenylation seems to be a key mechanism by which statins alter immune function. In this Review, the effect of statin therapy on immune function, and how this relates to the pathogenesis of autoimmune disease, is reviewed alongside current opinion of what the key biological targets of statins are.

[1]  D. Robinson,et al.  Further checkpoints in Th1 development. , 2002, Immunity.

[2]  M. Moskowitz,et al.  Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[3]  W. Daniel,et al.  HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. , 2004, Atherosclerosis.

[4]  F. Mach,et al.  Anti-inflammatory properties of statins. , 2004, Seminars in vascular medicine.

[5]  F. Fazekas,et al.  CME Statins as immunomodulators Comparison with interferon-1 b in MS , 2002 .

[6]  R. Pardi,et al.  Simvastatin Modulates Cytokine-Mediated Endothelial Cell Adhesion Molecule Induction: Involvement of an Inhibitory G Protein1 , 2000, The Journal of Immunology.

[7]  M. Ehrenstein,et al.  Atorvastatin Inhibits Autoreactive B Cell Activation and Delays Lupus Development in New Zealand Black/White F1 Mice1 , 2004, The Journal of Immunology.

[8]  Qingbo Xu,et al.  Is atherosclerosis an immunologically mediated disease? , 1995, Immunology today.

[9]  C. Gabay,et al.  Assessment of the efficacy of different statins in murine collagen-induced arthritis. , 2004, Arthritis and rheumatism.

[10]  John G. Collard,et al.  Reactive oxygen species mediate Rac-induced loss of cell-cell adhesion in primary human endothelial cells. , 2002, Journal of cell science.

[11]  M. Hecker,et al.  Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[12]  T. Albini,et al.  The effects of atorvastatin in experimental autoimmune uveitis , 2005, British Journal of Ophthalmology.

[13]  M. Isobe,et al.  HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation. , 2004, Cardiovascular research.

[14]  R. Gerszten,et al.  HMG-CoA Reductase Inhibitor Modulates Monocyte-Endothelial Cell Interaction Under Physiological Flow Conditions In Vitro: Involvement of Rho GTPase-Dependent Mechanism , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[15]  P. Adamson,et al.  Lymphocyte migration into the central nervous system: implication of ICAM-1 signalling at the blood-brain barrier. , 2002, Vascular pharmacology.

[16]  J. Larosa,et al.  Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. , 1999, JAMA.

[17]  J. Liao.  Isoprenoids as mediators of the biological effects of statins. , 2002, The Journal of clinical investigation.

[18]  E. Dejana,et al.  Regulation of cadherin function by Rho and Rac: modulation by junction maturation and cellular context. , 1999, Molecular biology of the cell.

[19]  R. Pardi,et al.  Inhibition of interferon-gamma-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors. , 2001, Transplantation.

[20]  C. Stadelmann,et al.  Simvastatin treatment does not protect retinal ganglion cells from degeneration in a rat model of autoimmune optic neuritis , 2005, Experimental Neurology.

[21]  H. Waterham,et al.  Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. , 2002, Arthritis and rheumatism.

[22]  T. Tsuruo,et al.  Rap1 translates chemokine signals to integrin activation, cell polarization, and motility across vascular endothelium under flow , 2003, The Journal of cell biology.

[23]  Joerg Kallen,et al.  Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site , 2001, Nature Medicine.

[24]  P. Kubes,et al.  Nitric oxide: an endogenous modulator of leukocyte adhesion. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[25]  B. Buckley,et al.  Statins do more than just lower cholesterol , 1996, The Lancet.

[26]  H. Mcdevitt,et al.  In vivo effects of antibodies to immune response gene products: prevention of experimental allergic encephalitis. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[27]  S. Wright,et al.  Statins suppress THP‐1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation , 2001, Journal of leukocyte biology.

[28]  P. Lipsky,et al.  A product of mevalonate proximal to isoprenoids is the source of both a necessary growth factor and an inhibitor of cell proliferation. , 1991, Transactions of the Association of American Physicians.

[29]  L. Steinman,et al.  Anti I-A antibody suppresses active encephalomyelitis: treatment model for diseases linked to IR genes , 1983, The Journal of experimental medicine.

[30]  R. Knobler,et al.  Encephalitogenic T cell clones specific for myelin basic protein. An unusual bias in antigen recognition , 1985, The Journal of experimental medicine.

[31]  F. Mach,et al.  Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. , 2006, Atherosclerosis.

[32]  R. González-Amaro,et al.  Therapy with statins in patients with refractory rheumatic diseases: a preliminary study , 2003, Lupus.

[33]  N. Turner,et al.  The FASEB Journal express article 10.1096/fj.04-2852fje. Published online February 23, 2005. ©2005 FASEB , 2022 .

[34]  C. Baldari,et al.  Simvastatin inhibits T‐cell activation by selectively impairing the function of Ras superfamily GTPases , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[35]  M. Endres,et al.  Treatment of Relapsing Paralysis in Experimental Encephalomyelitis by Targeting Th1 Cells through Atorvastatin , 2003, The Journal of experimental medicine.

[36]  R. Keep,et al.  Potential role of MCP-1 in endothelial cell tight junction `opening': signaling via Rho and Rho kinase , 2003, Journal of Cell Science.

[37]  B. Binder,et al.  Simvastatin Reduces the Expression of Adhesion Molecules in Circulating Monocytes From Hypercholesterolemic Patients , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[38]  U. Laufs,et al.  Post-transcriptional Regulation of Endothelial Nitric Oxide Synthase mRNA Stability by Rho GTPase* , 1998, The Journal of Biological Chemistry.

[39]  C. Nobes,et al.  Dendritic cells: New roles for Cdc42 and Rac in antigen uptake? , 2000, Current Biology.

[40]  S. Sebti,et al.  Inhibition of geranylgeranyltransferase I decreases generation of vascular reactive oxygen species and increases vascular nitric oxide production. , 2005, The Journal of surgical research.

[41]  I. Singh,et al.  Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin , 1999, Neuroscience Letters.

[42]  M. Linton,et al.  Current perspectives on statins. , 2000, Circulation.

[43]  I. Singh,et al.  Immunomodulation of experimental autoimmune encephalomyelitis in the Lewis rats by Lovastatin , 2002, Neuroscience Letters.

[44]  P. Adamson,et al.  Inhibition of Rho GTPases with Protein Prenyltransferase Inhibitors Prevents Leukocyte Recruitment to the Central Nervous System and Attenuates Clinical Signs of Disease in an Animal Model of Multiple Sclerosis1 , 2002, The Journal of Immunology.

[45]  T. Maniatis,et al.  Transcriptional regulation of endothelial cell adhesion molecules : NF-icB and cytokine-inducible enhancers , 2004 .

[46]  P. Libby,et al.  Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. , 1995, The Journal of clinical investigation.

[47]  R. Ransohoff,et al.  The many roles of chemokines and chemokine receptors in inflammation. , 2006, The New England journal of medicine.

[48]  U. Ikeda,et al.  Nitric oxide attenuates adhesion molecule expression in human endothelial cells. , 1996, Cytokine.

[49]  T. Kodama,et al.  The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells. , 2002, Journal of atherosclerosis and thrombosis.

[50]  P. Adamson,et al.  Lovastatin inhibits brain endothelial cell Rho‐mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[51]  R. Chakrabarti,et al.  Interrelationships between mevalonate metabolism and the mitogenic signaling pathway in T lymphocyte proliferation. , 1991, The Journal of biological chemistry.

[52]  P. Libby,et al.  Oxidized Low-Density Lipoprotein Augments and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Limit CD40 and CD40L Expression in Human Vascular Cells , 2002, Circulation.

[53]  T. Maudelonde,et al.  The Lancet: saturday 11 November 1989 , 1989 .

[54]  M. Feldmann,et al.  ROLE OF ABERRANT HLA-DR EXPRESSION AND ANTIGEN PRESENTATION IN INDUCTION OF ENDOCRINE AUTOIMMUNITY , 1983, The Lancet.

[55]  Wulf Palinsk.  New Evidence for Beneficial Effects of Statins Unrelated to Lipid Lowering , 2001 .

[56]  M. Goldstein,et al.  Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin , 2006, The Journal of experimental medicine.

[57]  M. Hecker,et al.  3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase-Independent Inhibition of CD40 Expression by Atorvastatin in Human Endothelial Cells , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[58]  P. Casey,et al.  Protein prenylation: molecular mechanisms and functional consequences. , 1996, Annual review of biochemistry.

[59]  A. Namboodiri,et al.  Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. , 1997, The Journal of clinical investigation.

[60]  Wei Liu,et al.  Effects of atorvastatin on the Th1/Th2 polarization of ongoing experimental autoimmune myocarditis in Lewis rats. , 2005, Journal of autoimmunity.

[61]  S. Youssef,et al.  The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease , 2002, Nature.

[62]  J. Greenwood,et al.  ICAM-1-Coupled Cytoskeletal Rearrangements and Transendothelial Lymphocyte Migration Involve Intracellular Calcium Signaling in Brain Endothelial Cell Lines1 , 2000, The Journal of Immunology.

[63]  W. Erl,et al.  HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. , 1997, Journal of the American College of Cardiology.

[64]  J. Liao,et al.  Inhibition of Endothelial Vascular Cell Adhesion Molecule-1 Expression by Nitric Oxide Involves the Induction and Nuclear Translocation of IκBα* , 1997, The Journal of Biological Chemistry.

[65]  F. Mach,et al.  Statins as a newly recognized type of immunomodulator , 2000, Nature Medicine.

[66]  I. Singh,et al.  Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis , 2001, Journal of neuroscience research.

[67]  F. Fazekas,et al.  Statins as immunomodulators: Comparison with interferon-&bgr;1b in MS , 2002, Neurology.

[68]  P. Adamson,et al.  Pharmacological Targeting of ICAM-1 Signaling in Brain Endothelial Cells: Potential for Treating Neuroinflammation , 2005, Cellular and Molecular Neurobiology.

[69]  M. Teixeira,et al.  Anti-inflammatory and analgesic effects of atorvastatin in a rat model of adjuvant-induced arthritis. , 2005, European journal of pharmacology.

[70]  U. Laufs,et al.  Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. , 1998, Circulation.

[71]  L. Steinman,et al.  The T lymphocyte in experimental allergic encephalomyelitis. , 1990, Annual review of immunology.

[72]  F. Mach.  Statins as immunomodulators. , 2002, Transplant immunology.

[73]  Z Mishal,et al.  Cerivastatin, an Inhibitor of HMG-CoA Reductase, Inhibits Urokinase/Urokinase-receptor Expression and MMP-9 Secretion by Peripheral Blood Monocytes , 2000, Thrombosis and Haemostasis.

[74]  O. Grip,et al.  Atorvastatin activates PPAR-γ and attenuates the inflammatory response in human monocytes , 2002, Inflammation Research.

[75]  R. Madhok,et al.  Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial , 2004, The Lancet.

[76]  H. Hartung,et al.  Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases. , 2004, Archives of neurology.

[77]  Shailendra Giri,et al.  Potential Targets of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor for Multiple Sclerosis Therapy , 2004, The Journal of Immunology.

[78]  L. Steinman,et al.  Cholesterol-lowering statins possess anti-inflammatory activity that might be useful for treatment of MS. , 2002, Neurology.

[79]  Y. Shoenfeld,et al.  Immunomodulation for treatment and prevention of atherosclerosis. , 2002, Autoimmunity reviews.

[80]  R. Palmer,et al.  Nitric oxide and prostacyclin. Divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[81]  W. Palinski,et al.  New evidence for beneficial effects of statins unrelated to lipid lowering. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[82]  Y. Shoenfeld,et al.  Statins and autoimmune diseases. , 2004, Autoimmunity reviews.

[83]  R. Jacob,et al.  Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. , 2005, The American journal of cardiology.

[84]  P. Hordijk,et al.  VCAM-1-mediated Rac signaling controls endothelial cell-cell contacts and leukocyte transmigration. , 2003, American journal of physiology. Cell physiology.

[85]  F. Bernini,et al.  HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[86]  H. Waterham,et al.  Isoprenoid biosynthesis in hereditary periodic fever syndromes and inflammation , 2003, Cellular and Molecular Life Sciences CMLS.

[87]  R. Zinkernagel,et al.  Arterial inflammation and atherosclerosis. , 2002, Trends in cardiovascular medicine.

[88]  J. Neefjes,et al.  Statins affect cell-surface expression of major histocompatibility complex class II molecules by disrupting cholesterol-containing microdomains. , 2005, Human immunology.

[89]  Shailendra Giri,et al.  Inhibition of phosphoinositide 3 kinase‐Akt (protein kinase B)–nuclear factor‐κB pathway by lovastatin limits endothelial–monocyte cell interaction , 2005, Journal of neurochemistry.

[90]  I. Bernard,et al.  Cellular and genetic factors involved in the difference between Brown Norway and Lewis rats to develop respectively type‐2 and type‐1 immune‐mediated diseases , 2001, Immunological reviews.

[91]  S. Youssef,et al.  Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. , 2006, The Journal of clinical investigation.

[92]  I. Singh,et al.  Regulation of gene expression associated with acute experimental autoimmune encephalomyelitis by Lovastatin , 2004, Journal of neuroscience research.

[93]  J. Pollard,et al.  Rho, Rac and Cdc42 regulate actin organization and cell adhesion in macrophages. , 1997, Journal of cell science.

[94]  A. Strosberg,et al.  ICAM-1 signaling pathways associated with Rho activation in microvascular brain endothelial cells. , 1998, Journal of immunology.

[95]  P. Adamson,et al.  Lymphocyte migration through brain endothelial cell monolayers involves signaling through endothelial ICAM-1 via a rho-dependent pathway. , 1999, Journal of immunology.

[96]  B. Kaina,et al.  Lovastatin inhibits Rho‐regulated expression of E‐selectin by TNF‐α and attenuates tumor cell adhesion , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[97]  M. Waldor,et al.  Disappearance and reappearance of B cells after in vivo treatment with monoclonal anti-I-A antibodies. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[98]  A. Mantovani,et al.  Inhibition of Monocyte Chemotactic Protein-1 Synthesis by Statins , 2000, Laboratory Investigation.

[99]  R. Pedrosa,et al.  Therapeutic potential of lovastatin in multiple sclerosis , 2003, Journal of Neurology.

[100]  K. Kaibuchi,et al.  Small GTP-binding proteins. , 1992, International review of cytology.

[101]  J. Navarro-Antolín,et al.  Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. , 1998, The Journal of clinical investigation.

[102]  I. Shiojima,et al.  The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. , 2000, Nature Medicine.

[103]  T. L. Deem,et al.  Calcium mobilization and Rac1 activation are required for VCAM-1 (vascular cell adhesion molecule-1) stimulation of NADPH oxidase activity. , 2004, The Biochemical journal.

[104]  V. Durkalski,et al.  Oral simvastatin treatment in relapsing-remitting multiple sclerosis , 2004, The Lancet.